Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-000-7 | CAS number: 13573-12-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
There is no data regarding acute toxicity via oral or inhalation route available for magnesium dimetaphosphate. Read across data with calcium bis (dihydrogenorthophosphate) CAS 7758 -23 -8 and trimagnesium bis(orthophosphate) CAS 7757 -87 -1 is used and considered reliable.
Oral (OECD420, CAS 7757 -87 -1, RL1), rat LD50 > 2000 mg/kg bw (limit test)
Inhalation (OECD 403, CAS 7758 -23 -8, RL1), rat LC50 > 2.6 mg/L air (limit test)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- refer to read across justification in IUCLID chapter 13
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There was no mortality.
- Clinical signs:
- No signs of systemic toxicity were noted during the observation period.
- Body weight:
- The animals showed expected gains in bodyweight over the observation period.
- Gross pathology:
- No abnormalities were noted at necropsy.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute oral median lethal dose (LD50) of magnesium dimetaphosphate in the female Wistar strain rat was estimated to be greater than 2000 mg/kg bodyweight (Globally Harmonised Classification System − Unclassified).
- Executive summary:
The LD50 was estimated to be greater than 2000 mg/kg bw for magnesium dimetaphosphate as found in the source study performed with trimagnesium bis(orthophosphate). As explained in the justification for type of information, the differences in molecular structure between magnesium dimetaphosphate and trimagnesium bis(orthophosphate) are unlikely to lead to differences in a oral LD50.
Reference
Table 1. Individual clinical observations and mortality data – 300 mg/kg
Dose level mg/kg |
Animal number and sex |
Effects noted after dosing (hours) |
Effects noted during periods after doing (days) |
||||||||||||||||
½ |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
||
300 |
1-0 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
X |
0 |
0 |
0 |
0 |
0 |
0 |
0 = No signs of systemic toxicity
X= Due to a technician error clinical observation not performed
Table 2. Individual bodyweight and bodyweight changes– 300 mg/kg bw
Dose level mg/kg |
Animal number and sex |
Bodyweight (g) at day
|
Bodyweight gain (g) during week
|
|||
0 |
7 |
14 |
1 |
2 |
||
300 |
1-0 Female |
186 |
194 |
209 |
8 |
15 |
Table 3. Individual Necropsy Findings – 300 mg/kg
Dose level mg/kg |
Animal number and sex |
Time of death |
Macroscopic observations |
300 |
1-0 Female |
Killed day 14 |
No abnormalities detected |
Table 4. Individual clinical observations and mortality data.– 2000 mg/kg bw
Dose level mg/kg |
Animal number and sex |
Effects noted after dosing (hours) |
Effects noted during periods after doing (days) |
||||||||||||||||
½ |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
||
2000 |
2-0 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3-0 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-1 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-2 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-3 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 = no signs of systemic toxicity
Table 5. Individual bodyweight and bodyweight changes– 2000 mg/kg bw
Dose level mg/kg |
Animal number and sex |
Bodyweight (g) at day
|
Bodyweight gain (g) during week
|
|||
0 |
7 |
14 |
1 |
2 |
||
2000 |
2-0 Female |
180 |
194 |
202 |
14 |
8 |
3-0 Female |
149 |
177 |
193 |
28 |
16 |
|
3-1 Female |
153 |
173 |
189 |
20 |
16 |
|
3 -2 Female |
162 |
186 |
202 |
24 |
16 |
|
3 -3 Female |
159 |
179 |
187 |
20 |
8 |
Table 6. Individual Necropsy Findings– 2000 mg/kg
Dose level mg/kg |
Animal number and sex |
Time of death |
Macroscopic observations |
2000 |
2-0 Female |
Killed day 14 |
No abnormalities detected |
3-0 Female |
Killed day 14 |
No abnormalities detected |
|
3-1 Female |
Killed day 14 |
No abnormalities detected |
|
3-2 Female |
Killed day 14 |
No abnormalities detected |
|
3-3 Female |
Killed day 14 |
No abnormalities detected |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The available information comprises an adequate and reliable study from a reference substance similar in structure and intrinsic properties. Read-across is justified based on structural similarities of magnesiumphosphate compounds and their similarities in PC/ECO/TOX properties (refer to read across justification for further details). The selected study is thus sufficient to fulfill the standard information requirements set out in Annex VII, 8.5, in accordance with Annex XI, 1.5, of Regulation (EC) No. 1907/2006.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- see analogue justification attached to chapter 13
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 2.6 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- All animals survived the scheduled observation period.
- Clinical signs:
- other: Slight to moderate ruffled fur was noted in all animals on test day 1, one hour after the end of the exposure and persisted slightly until test day 2 in nine animals. From test day 3 onwards, all animals were free from clinical signs until their scheduled
- Body weight:
- From test day 1 to test day 2, marginal to slight body weight loss was noted in all animals. Thereafter all animals gained weight until scheduled necropsy.
- Gross pathology:
- There were no macroscopic findings.
- Other findings:
- Not applicable.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The LC50 of magnesium dimetaphosphate as obtained in this study was estimated to be greater than 2.6 mg/L air (gravimetrically determined mean aerosol concentration). This was the highest technically achievable test concentration. There was no indication of relevant sex-related differences in toxicity of the test item.
In accordance with Regulation (EC) No. 1272/2008 (EU CLP) magnesium metaphosphate is not considered to be classified as acutely toxic via the inhalation route. - Executive summary:
The LC50 was estimated to be greater than 2.6 mg/L air for magnesium dimetaphosphate as found in the source study performed with calcium bis(dihydrogenorthophosphate). As explained in the justification for type of information, the differences in molecular structure between magnesium dimetaphosphate and calcium bis(dihydrogenorthophosphate) are unlikely to lead to differences in the LC50 for inhalation.
Reference
The nominal aerosol concentration was 7.5 mg/L air.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 2 600 mg/m³
- Quality of whole database:
- The available information comprises an adequate and reliable study from a reference substance similar in structure and intrinsic properties. Read-across is justified based on structural similarities of calcium- and magnesiumphosphate compounds and their similarities in PC/ECO/TOX properties (refer to read across justification for further details). The selected study is thus sufficient to fulfill the standard information requirements set out in Annex VII, 8.5, in accordance with Annex XI, 1.5, of Regulation (EC) No. 1907/2006.
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Oral:
No study is available with magnesium metaphosphate (CAS 13573 -12 -1). Reliable data is available for trimagnesium bis(orthophosphate) (CAS 7757 -87 -1).
Trimagnesium bis(orthophosphate) and magnesium dimetaphosphate are structurally similar ionic compounds. The differences between the two compounds will not have an impact on any acute toxicity potential and therefore, the result from the acute oral toxicity study can reliably be read across to magnesium dimetaphosphate.
In an acute oral toxicity study (OECD 420, Harlan, 2013), one fasted female Wistar rat was treated with 300 mg/kg bw of trimagnesium bis(orthophosphate) in water by gavage. After no toxicity was oberserved in this animal a further female Wistar rat was treated with 2000 mg/kg bw. Since there was also no toxicity observed further 4 female rats were tested with 2000 mg/kg bw test substance and were observed for 14 days. No animals died and no clinical sings were observed during the observation period. All rats appeared normal at necropsy.
The following LD50 after oral administration of trimagnesium bis(orthophosphate) was determined to be > 2000 mg/kg bw.
Inhalation:
No study is available with trimagnesium bis(orthophosphate) (CAS 7757 -87 -1). Reliable data is available for calcium bis(dihydrogenorthophosphate) (CAS 7758 -23 -8).
Calcium bis(dihydrogenorthophosphate) and trimagnesium bis(orthophosphate) are structurally similar ionic compounds with the only differences being that calcium is replaced with magnesium. The phosphate groups are structurally identical between the two compounds and any acute toxicity potential will be the same. Magnesium and calcium are both alkali metals from group 2 and periods 3 and 4 of the periodic table, respectively and have only one oxidation state (+2). Magnesium and calcium are among the most abundant elements and are the important essential nutrients for higher plants, algae, animals and human. Both elements are similar in chemical nature and show the related metabolism and similar environmental behaviour. The differences between the two compounds will not have an impact on any acute toxicity potential and therefore, the result from the acute inhalation toxicity study can reliably be read across to trimagnesium bis(orthophosphate).
In an inhalation toxicity study (according to OECD 403, Harlan, 2010), groups of 11 week old Wistar rats (5/sex) were exposed by inhalation route (nose only) to the test substance as a dust and observed for 14 days. The maximal achievable dose was 2.6 mg/L. The rats were exposed for 4 hours. The ranges of aerosol concentration, temperature, relative humidity, oxygen content and airflow rate measured during the exposure were considered to be satisfactory for a study of this type. In addition, the test item was considered to be respirable to rats. All animals survived the scheduled observation period. Slight to moderate ruffled fur was noted in all animals after the end of the exposure and was still present in most animals up to test day 2. Thereafter, all animals were free from clinical signs. Transient body weight loss was noted in all animals from test day 1 to test day 2. Normal body weight development was observed thereafter. No macroscopical findings were present at necropsy.
In conclusion, the LC50 of calcium bis(dihydrogenorthophosphate) and thus of magnesium dimetaphosphate) obtained in this study was estimated to be greater than 2.6 mg/L air (gravimetrically determined mean aerosol concentration). There was no indication of relevant sex-related differences in toxicity of the test item.
In conclusion, since trimagnesium bis(orthophosphate) and calcium bis(dihydrogenorthophosphate) are reliable read across substances and no acute oral or inhalation toxicity are observed, magnesium dimetaphosphate is considered to be also not acute toxic via oral and inhalation route.
Justification for classification or non-classification
In accordance with Regulation (EC) No.1272/2008 (EU CLP) magnesium dimetaphosphate is not considered to be classified for acute toxicity via oral or inhalation route. The data provided for this endpoint are considered to be conclusive and no further investigation is required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.